Table 2. Peroxiredoxin 1 performances to diagnose and to time cerebral infarction.
| Control population vs. Stroke patients | Stroke patients median level ± standard deviation n = 82 | 6.9 ± 13.7 ng/mL | p < 0.01 |
| Control population median level ± standard deviation n = 109 | 3.5 ± 4.5 ng/mL | ||
| Diagnostic performance: identification of cerebral infarction <3 hours | Samples <3 hours median level ± standard deviation Overall n = 32 | 11.7 ± 15.6 ng/mL | p < 0.01 |
| TACI n = 11 | 8.6 ± 9.7 ng/mL | p = 0.1 | |
| PACI n = 14 | 10.4 ± 18.2 ng/mL | p = 0.14 | |
| LACI n = 4 | 11.7 ± 19,5 ng/mL | p = 0.28 | |
| POCI n = 3 | 25.5 ± 12.1 ng/mL | p = 0.08 | |
| Samples >3 hours median level ± standard deviation Overall n = 50 | 5 ± 11.6 ng/mL | ||
| TACI n = 13 | 4.4 ± 4,1 ng/mL | ||
| PACI n = 24 | 6.4 ± 12 ng/mL | ||
| LACI n = 5 | 7.6 ± 3 ng/mL | ||
| POCI n = 8 | 4 ± 19.9 ng/mL | ||
| ROC analysis AUC (95%CI), Sensitivity, Specificity | 69% (57–81%), 53%, 86% | ||
| Diagnostic performance: identification of cerebral infarction <6 hours | Samples <6 hours median level ± standard deviation Overall n = 39 | 9.6 ± 14.9 ng/mL | p < 0.01 |
| TACI n = 13 | 8.5 ± 9.2 ng/mL | p = 0.15 | |
| PACI n = 18 | 10 ± 16.8 ng/mL | p = 0.07 | |
| LACI n = 4 | 11.7 ± 19.5 ng/mL | p = 0.28 | |
| POCI n = 4 | 24 ± 17 ng/mL | p = 0.07 | |
| Samples >6 hours median level ± standard deviation Overall n = 43 | 4.9 ± 11.9 ng/mL | ||
| TACI n = 11 | 4.4 ± 4.3 ng/mL | ||
| PACI n = 20 | 5.7 ± 12.2 ng/mL | ||
| LACI n = 5 | 7.6 ± 3.1 ng/mL | ||
| POCI n = 7 | 4.8 ± 21.2 ng/mL | ||
| ROC analysis AUC (95%CI), Sensitivity, Specificity | 68% (56–80%), 49%, 88% |
PRDX1: peroxiredoxin 1, TACI: total anterior circulation infarcts, PACI: partial anterior circulation infarcts, LACI: lacunar circulation infarcts, POCI: posterior circulation infarcts (Oxfordshire Community Stroke Project Classification), 95% CI: 95% confidence interval, n: number of plasma samples, p: Mann–Whitney U test p value comparing PRDX1 levels in control population vs. stroke patients, in plasma samples <vs. > 3 hours, and <vs. > 6 hours after stroke onset.